| Subject: | FDA Publishes Notification of Recall of One Lot of Famotidine (Pepcid) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 4 May 2005 - 10:00 am |
| The FDA has issued a notice of Bedford Laboratories' voluntary recall of one lot of the H2 receptor antagonist Famotidine (Pepcid). The recall is for Famotidine injection, 20 mg/2 mL dosage, due to lack of assurance of the product's sterility. Famotidine is prescribed for treatment of ulcers, gastrointestinal reflux disease (GERD) and conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome (tumors in the pancreas or small intestine causing increased stomach acid... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
